Provided by Tiger Trade Technology Pte. Ltd.

Global X Genomics & Biotechnology ETF

65.18
+0.42000.65%
Volume:26.37K
Turnover:1.73M
Market Cap:92.87M
PE:- -
High:66.32
Open:66.20
Low:64.42
Close:64.76
52wk High:68.00
52wk Low:36.00
Shares:1.42M
Float Shares:1.42M
Volume Ratio:0.96
T/O Rate:1.85%
Dividend:0.65
Dividend Rate:0.99%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Pharma Industry Stares Down Biggest Patent Cliff in Decades

Dow Jones
·
Aug 29

US Stocks Weekly: AI Refuel

Reuters
·
Aug 29

BioNTech Stock Falls on Cancer Vaccine Setback Days After Moderna's Big Win

Dow Jones
·
Aug 29

BioNTech on Track for Worst Day Since March After Ending Colorectal Cancer Trial

Reuters
·
Aug 29

Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer

THOMSON REUTERS
·
Aug 28

Moderna Stock Falls on $2B Notes Deal: Is the Cancer Rally Still Intact?

TradingKey
·
Aug 28

Argus Research Upgrades Moderna to Buy From Hold, $180 Price Target

MT Newswires Live
·
Aug 28

Moderna Announces Pricing of Upsized $2.6 Billion Offering of Convertible Senior Notes

Reuters
·
Aug 28

Moderna Price Target Announced at $180.00/Share by Argus Research

Dow Jones
·
Aug 28

U.S. Stocks on the MOVE-Cytokinetics, Moderna, Ulta Beauty

Reuters
·
Aug 28

Success After a Century of Failures: Inside Moderna and Merck's Cancer Vaccine Breakthrough

Reuters
·
Aug 28

Moderna Prices $2.6 Billion Convertible Notes due 2032

MT Newswires Live
·
Aug 28

Moderna Rises After Upsized $2.6 Bln Convertible Bond Sale

Reuters
·
Aug 28

Illumina Director Keith Meister Disposes of USD 76.95 Million in Common Shares

Reuters
·
Aug 28

FDA Approves Seasonal Covid-19 Vaccines from Moderna, Pfizer, BioNTech

Dow Jones
·
Aug 28

Moderna Inc. Stock Slips 4.6%, Underperforms Peers

Dow Jones
·
Aug 28

Twist Bioscience CEO Emily Leproust Sells USD 6.28 Million in Common Shares

Reuters
·
Aug 28

Moderna Wins FDA Approval for Updated 2026-2027 COVID-19 Vaccines Targeting JN.1-Lineage XFG Subvariant

Reuters
·
Aug 28

Moderna - FDA Approved Sbla for 2026-2027 Formulas for Spikevax and Mnexspike

THOMSON REUTERS
·
Aug 28

Moderna - Updated Formula for Spikevax is NOW Approved for Individuals 6 Months Through 64 Years of Age with at Least One Underlying Condition

THOMSON REUTERS
·
Aug 28